Archive

Neovasc Announces Resolution of Last Remaining Active Litigation

Posted on April 17, 2019
in
by

NASDAQ, TSX: NVCN VANCOUVER, April 17, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina,...

Read More

Neovasc Announces Peer Reviewed Publication in the International Journal of Cardiology Demonstrating that the Neovasc Reducer™ Improves Diastolic Function in patients suffering from severe angina

Posted on April 17, 2019
in
by

NASDAQ, TSX: NVCN VANCOUVER, April 17, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina,...

Read More

Neovasc Announces Fourth Quarter and Fiscal Year 2018 Financial Results

Posted on March 21, 2019
in
by

NASDAQ, TSX: NVCN Recent Highlights The U.S. Food and Drug Administration (the "FDA") granted Breakthrough Device designation to the Neovasc Reducer™ (the "Reducer") for the treatment of refractory angina Reducer implanted in 100th patient in Germany 5-Year anniversary of Tiara™ (the "Tiara") patient celebrated as the...

Read More

Neovasc Wins German Court Appeal; Announces German Court’s Decision to Dismiss CardiAQ’s Claim to Co-inventorship of a European Patent for Tiara™

Posted on March 21, 2019
in
by

NASDAQ, TSX: NVCN VANCOUVER, March 21, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory...

Read More